Ian F. Smith is Executive Chairman of Solid’s Board and has served as a member of Solid’s Board of Directors since April 2020 and served as a consultant to Solid from February 2020 to December 2021.

Mr. Smith currently serves as chairman of the Board of Directors of Rivus Pharmaceuticals, Inc., and iVexSol, Inc., and is a member of the Board of Directors of Stoke Therapeutics, Inc., Foghorn Therapeutics Inc., and Alkeus Pharmaceuticals, Inc., which are all biotechnology companies. He is also a Senior Advisor to Bain Capital Life Sciences and provides advisory and consulting services to biotechnology companies. Mr. Smith also served as director and Executive Chair of the Board of Directors of ViaCyte, Inc., a private biotechnology company, from July 2019 to September 2022 (acquired September 2022). Between 2001 and 2019, Mr. Smith served as Chief Financial Officer and Chief Operating Officer at Vertex Pharmaceuticals, a public biotechnology company.

He received a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK).